Propanc Biopharma financials
$0.5123−3.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 |
|---|---|
| Revenue | $0.00 |
| Gross profit | $0.00 |
| Gross margin | — |
| Operating income | -$18.2M |
| Net income | -$19.8M |
| Net margin | — |
| Diluted EPS | $-17.62 |
| EBITDA | -$18.2M |
| Operating cash flow | -$5.7M |
| Free cash flow | -$5.7M |
| Diluted shares | 1.1M |
Balance sheet
| Period end | Jun 30 |
|---|---|
| Cash & equivalents | $832.0K |
| Short-term investments | $0.00 |
| Total debt | $0.00 |
| Total assets | $12.8M |
| Total liabilities | $3.4M |
| Shareholders' equity | $9.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology